NewMarket Earnings Call Transcripts
Fiscal Year 2026
-
Net income and petroleum additives sales declined year-over-year, while specialty materials sales rose due to an acquisition but with lower operating profit. Strong cash flows supported significant shareholder returns, and management remains focused on long-term value amid market volatility.
Fiscal Year 2025
-
Pre-tax and net income declined year-over-year due to a higher effective tax rate and market softness, especially in Petroleum Additives, while Specialty Materials saw strong growth from acquisitions and volume. Cash flow supported debt reduction and shareholder returns.
-
Q3 2025 net income and sales declined year-over-year, mainly due to one-time charges, lower shipments, and increased R&D. Specialty materials segment benefited from acquisitions, and a 9% dividend increase was announced.
-
Net income for Q2 2025 was $111 million, nearly flat year-over-year, while first half net income set a record at $237 million. Petroleum additives faced shipment declines and inflationary pressures, but specialty materials saw strong profit growth.
-
Q1 2025 net income rose to $126M, with strong Specialty Materials growth offsetting lower Petroleum Additives sales. AMPAC investment will boost capacity by 50% by 2026, and net debt-to-EBITDA improved to 1.1.
Fiscal Year 2024
-
Q4 and full-year 2024 net income and operating profit rose year-over-year, driven by efficiency gains and lower costs, despite lower sales. Specialty materials outperformed expectations following the AMPAC acquisition, and net debt-to-EBITDA improved to 1.2.
-
Q3 2024 net income rose to $132 million, with petroleum additives operating profit up due to lower costs. AMPAC acquisition boosted specialty materials sales, and net debt-to-EBITDA improved to 1.4. Capital expenditures for 2024 are projected at $50–$70 million.
-
Q2 2024 net income rose to $112 million, with petroleum additives operating profit up 12% year-over-year. Specialty materials turned profitable following the AMPAC acquisition, and net debt to EBITDA remains within target. Capital expenditures for 2024 are projected at $50–$70 million.